TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 26.67%2.22B | -1.22%3.39B | 9.98%1.75B | 26.92%3.43B | 15.62%1.59B | -5.07%2.7B | -4.29%1.38B | 0.33%2.85B | --1.44B | 50.39%2.84B |
Operating income | 26.67%2.22B | -1.22%3.39B | 9.98%1.75B | 26.92%3.43B | 15.62%1.59B | -5.07%2.7B | -4.29%1.38B | 0.33%2.85B | 1.44B | 50.39%2.84B |
Cost of sales | -1.11%-723.76M | 17.23%-1.32B | 11.75%-715.84M | -8.04%-1.6B | -15.54%-811.12M | -12.27%-1.48B | -14.21%-702.01M | -23.37%-1.32B | ---614.68M | -37.36%-1.07B |
Operating expenses | -1.11%-723.76M | 17.23%-1.32B | 11.75%-715.84M | -8.04%-1.6B | -15.54%-811.12M | -12.27%-1.48B | -14.21%-702.01M | -23.37%-1.32B | -614.68M | -37.36%-1.07B |
Gross profit | 44.30%1.5B | 12.70%2.07B | 32.49%1.04B | 49.67%1.84B | 15.70%782.92M | -19.96%1.23B | -18.06%676.7M | -13.53%1.53B | 825.8M | 59.50%1.77B |
Selling expenses | -110.45%-695.32M | 6.23%-865.24M | 18.16%-330.4M | -18.26%-922.68M | -17.20%-403.72M | -23.18%-780.18M | -23.84%-344.47M | 14.99%-633.39M | ---278.16M | -66.32%-745.1M |
Administrative expenses | -35.90%-138.32M | 3.95%-224.61M | 2.58%-101.79M | 0.53%-233.85M | 6.36%-104.48M | -30.67%-235.11M | -37.07%-111.57M | 11.24%-179.92M | ---81.39M | -88.88%-202.69M |
Research and development expenses | 20.52%-419.49M | 20.89%-1.02B | 19.59%-527.78M | -3.35%-1.28B | -13.97%-656.37M | -88.92%-1.24B | -164.01%-575.94M | -107.03%-657.51M | ---218.15M | -60.58%-317.6M |
Revaluation surplus | ---- | ---- | ---- | ---- | -159.28%-4.9M | 755.47%9.35M | 16.94%8.27M | -117.42%-1.43M | --7.07M | 344.29%8.19M |
-Changes in the fair value of other assets | ---- | ---- | ---- | ---- | -159.28%-4.9M | 755.47%9.35M | 16.94%8.27M | -117.42%-1.43M | --7.07M | 344.29%8.19M |
Impairment and provision | -53.27%873K | 79.84%-517K | 2,494.87%1.87M | -1,078.63%-2.56M | -104.56%-78K | 116.13%262K | 230.36%1.71M | 14.03%-1.62M | ---1.31M | -531.77%-1.89M |
-Other impairment is provision | -53.27%873K | 79.84%-517K | 2,494.87%1.87M | -1,078.63%-2.56M | -104.56%-78K | 116.13%262K | 230.36%1.71M | 14.03%-1.62M | ---1.31M | -531.77%-1.89M |
Special items of operating profit | -40.36%25.96M | -18.49%32.43M | 319.95%43.54M | -39.79%39.79M | -336.22%-19.79M | 123.83%66.09M | -56.70%8.38M | 77.82%29.53M | --19.35M | -48.71%16.61M |
Operating profit | 120.48%270.51M | 99.08%-5.22M | 130.19%122.69M | 40.57%-567.87M | -20.63%-406.43M | -1,189.67%-955.52M | -223.31%-336.92M | -83.43%87.69M | 273.22M | 36.97%529.29M |
Financing income | -59.17%18.38M | 225.39%90.06M | 374.82%45.02M | 104.51%27.68M | 86.95%9.48M | -12.72%13.53M | -25.91%5.07M | 86.38%15.51M | --6.85M | 66.61%8.32M |
Financing cost | 54.43%-15.61M | -107.34%-119.92M | -25.29%-34.25M | -43.65%-57.84M | -104.27%-27.33M | -910.14%-40.26M | -827.95%-13.38M | -35.07%-3.99M | ---1.44M | -27.20%-2.95M |
Special items of earning before tax | -39.04%8.75M | -86.94%4.99M | -44.43%14.35M | 44.88%38.2M | 48.44%25.82M | 238.96%26.36M | 163.27%17.39M | -27.76%7.78M | --6.61M | 3,677.89%10.77M |
Earning before tax | 90.80%282.03M | 94.62%-30.1M | 137.10%147.82M | 41.43%-559.83M | -21.54%-398.46M | -993.47%-955.89M | -214.94%-327.83M | -80.38%106.99M | 285.23M | 40.07%545.43M |
Tax | 30.15%-31.45M | -148.71%-35.26M | -363.90%-45.03M | -136.73%-14.18M | 211.43%17.06M | 175.39%38.6M | 121.64%5.48M | -60.01%-51.2M | ---25.31M | 12.76%-32M |
After-tax profit from continuing operations | 143.78%250.58M | 88.61%-65.36M | 126.95%102.79M | 37.42%-574.01M | -18.32%-381.4M | -1,744.24%-917.29M | -224.02%-322.35M | -89.13%55.79M | 259.91M | 45.56%513.43M |
Earning after tax | 143.78%250.58M | 88.61%-65.36M | 126.95%102.79M | 37.42%-574.01M | -18.32%-381.4M | -1,744.24%-917.29M | -224.02%-322.35M | -89.13%55.79M | 259.91M | 45.56%513.43M |
Minority profit | 261.10%45.48M | 186.15%17.68M | 170.20%12.59M | 61.63%-20.52M | 66.70%4.66M | -214.65%-53.48M | -94.76%2.8M | -72.05%46.64M | --53.37M | 146.50%166.87M |
Profit attributable to shareholders | 127.40%205.1M | 85.00%-83.04M | 123.36%90.19M | 35.92%-553.5M | -18.73%-386.06M | -9,545.72%-863.81M | -257.42%-325.15M | -97.36%9.15M | 206.55M | 21.59%346.56M |
Basic earnings per share | 126.32%0.43 | 84.62%-0.18 | 123.17%0.19 | 37.10%-1.17 | -15.49%-0.82 | -9,400.00%-1.86 | -244.90%-0.71 | -97.96%0.02 | 0.49 | 20.99%0.98 |
Diluted earnings per share | 126.32%0.43 | 84.62%-0.18 | 123.17%0.19 | 37.10%-1.17 | -15.49%-0.82 | -9,400.00%-1.86 | -244.90%-0.71 | -97.96%0.02 | 0.49 | 20.99%0.98 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.